# DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

> **NCT00302341** · PHASE3 · TERMINATED · sponsor: **Immtech Pharmaceuticals, Inc** · enrollment: 48 (actual)

## Conditions studied

- Pneumonia, Interstitial Plasma Cell
- Pneumocystis Carinii Pneumonia
- Pneumonia, Pneumocystis Carinii
- HIV Infections

## Interventions

- **DRUG:** Pafuramidine maleate (DB289)
- **DRUG:** Trimethoprim-Sulfamethoxazole (TMP-SMX)

## Key facts

- **NCT ID:** NCT00302341
- **Lead sponsor:** Immtech Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** FDA Clinical Hold as of 12/21/07 due to safety concerns
- **Last updated:** 2013-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00302341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00302341, "DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00302341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*